Abstract: Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., PSP). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: A method, according to some implementations, includes obtaining trial design simulation results for a set of trial designs and determining a set of Pareto designs in the set of trial designs based at least in part on the trial design simulation results and one or more performance parameters. The method further includes determining a set of convex hull designs in the set of trial designs, determining a set of recommended designs based at least in part on the set of Pareto designs and the set of convex hull designs, and transmitting the set of recommended designs.

Abstract: A method for searching clinical trial designs that includes: determining a first convex hull set from a first set of clinical trial designs for a first scenario; simulating the first convex hull set for a second scenario to determine first simulation results; removing the first convex hull set from the first set of clinical trial designs to generate a second set of clinical trial designs; determining a second convex hull set from the second set of clinical trial designs for the first scenario; simulating the second convex hull set for the second scenario to determine second simulation results; determining, based at least in part on the first simulation results and the second simulation results, a refined scenario convex hull set of clinical trial designs for the second scenario from the first convex hull set and the second convex hull set; and transmitting the refined scenario convex hull set.

Abstract: A monolithic metal-organic framework (MOF) composite body is disclosed, comprising: MOF crystallites adhered to each other via a binder comprising MOF; and at least 0.15 vol % nanoparticles encapsulated in the MOF body. The nanoparticles have an average particle size corresponding to an average particle diameter in the range 3-200 nm. The nanoparticles may have photocatalytic activity. The MOF composite body is of use for treating water containing an organic dye, the photocatalytic reaction supported by the photocatalytic nanoparticles being a degradation reaction of the organic dye.

Abstract: A monolithic metal-organic framework (MOF) composite body is disclosed, comprising: MOF crystallites adhered to each other via a binder comprising MOF; and at least 0.15 vol % nanoparticles encapsulated in the MOF body. The nanoparticles have an average particle size corresponding to an average particle diameter in the range 3-200 nm. The nanoparticles may have photocatalytic activity. The MOF composite body is of use for treating water containing an organic dye, the photocatalytic reaction supported by the photocatalytic nanoparticles being a degradation reaction of the organic dye.